Trial Profile

A Multicenter, Double-Blind, Double-Dummy Study to Explore the Long-Term Safety and Efficacy of TEV-48125 for the Prevention of Cluster Headache

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 21 Jan 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Fremanezumab (Primary)
Indications Cluster headache
Focus Adverse reactions
Acronyms ENFORCE
Sponsors Teva Branded Pharmaceutical Products R&D

Most Recent Events

21 Jan 2022 This trial has been completed in Finland (Date of the global end of the trial : 11-Jun-2019), according to European Clinical Trials Database record.
13 Mar 2020 This trial has been completed in Netherland (Global End Date: 23 Apr 2019), according to European Clinical Trials Database record.
10 May 2019 This trial has been completed in Sweden, according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com